Clinical Trials/NCT04623710

NCT04623710

Completed

Phase 1

A Phase 1, Open-Label, Multiple-Dose, Parallel Study to Determine the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ALXN2050 in Adult Participants

Alexion Pharmaceuticals, Inc.1 site in 1 country40 target enrollmentJuly 8, 2021

ConditionsRenal Impairment Healthy

InterventionsALXN2050

DrugsALXN2050

Overview

Phase: Phase 1
Intervention: ALXN2050
Conditions: Renal Impairment
Sponsor: Alexion Pharmaceuticals, Inc.
Enrollment: 40
Locations: 1
Primary Endpoint: Maximum (Peak) Steady-state Plasma Concentration (Cmax,ss) Of Plasma ALXN2050
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with impaired renal function.

Detailed Description

The study will initiate (Part 1) with participants with severe impaired renal function (Cohort 1) and their matched healthy control participants (Cohort 4). Following data review, the study may proceed (Part 2) with participants with moderate (Cohort 2) and mild (Cohort 3) impaired renal function if deemed necessary.

Registry

clinicaltrials.gov

Start Date

July 8, 2021

End Date

March 21, 2022

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Alexion Pharmaceuticals, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Body weight must be at least 50.0 kilograms (kg) and body mass index (BMI) within the range of 18.0 - 40.0 kg/meter squared (m\^2) (inclusive) at the time of signing the informed consent.
•Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•Must agree to receive prophylactic antibiotics to mitigate the potential risk of meningococcal infection.
•Participants with Impaired Renal Function
•Aside from impaired renal function, sufficiently healthy for study participation based upon medical history, physical examination, neurological examination, laboratory tests, vital signs, and electrocardiograms (ECGs).
•A clinical diagnosis of impaired stable renal function.
•No clinically significant change in renal status at least 1 month prior to first dose of study intervention and is not currently or has not previously been on hemodialysis or did not have any history of peritoneal dialysis.
•Stable creatinine clearance.
•Must be on a stable medication regimen. Concomitant medications must be approved by Alexion unless presented in the list of common concurrent medications for participants with impaired renal function.
•Matched Healthy Control Participants with Normal Renal Function

Exclusion Criteria

•History or presence of seizures, head injury, head trauma, or any other brain disorder.
•History of procedures that could alter absorption or excretion of orally administered drugs.
•History of meningococcal infection or a first-degree relative with a history of meningococcal infection.
•Body temperature ≥38.0°Celcius at screening or check-in or history of febrile illness or other evidence of infection, systemic or otherwise, within 14 days prior to the first dose of study intervention.
•Participants with CH50 results outside the reference ranges at screening, unless approved by Alexion
•Significant blood loss or donation of blood within 3 months prior to the first dose of study intervention, donation of plasma within 30 days prior to the first dose of study intervention, receipt of blood products within 6 months prior to first dose of study intervention, or receipt of a vaccine within 30 days prior to the first dose of study intervention.
•Current enrollment or past participation within the last 30 days (or 5 half-lives, whichever is longer) prior to the first dose of study intervention in the current clinical study or any other clinical study involving an investigational study intervention or any other type of medical research.
•History or presence of drug or alcohol abuse within 1 year prior to the first dose of study intervention, current tobacco user, or positive results for alcohol and/or drug screen at screening or check-in.
•Pregnant or lactating.
•Does not produce sufficient urine output to permit urine sampling at screening and/or check-in or has a history of urinary incontinence prior to check-in.

Arms & Interventions

Cohort 1: Severe Impaired Renal Function

Participants will receive ALXN2050.

Intervention: ALXN2050

Cohort 2: Moderate Impaired Renal Function

Participants will receive ALXN2050.

Intervention: ALXN2050

Cohort 3: Mild Impaired Renal Function

Participants will receive ALXN2050.

Intervention: ALXN2050

Cohort 4: Healthy Control

Participants will receive ALXN2050.

Intervention: ALXN2050

Outcomes

Primary Outcomes

Maximum (Peak) Steady-state Plasma Concentration (Cmax,ss) Of Plasma ALXN2050

Time Frame: Up to 72 hours postdose

Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state

Time Frame: Up to 72 hours postdose

Area Under The Concentration-time Curve Calculated To The Last Observable Concentration At Time t (AUCt) Of Plasma ALXN2050 After Steady-state

Time Frame: Up to 72 hours postdose

Time To Reach Maximum (Peak) Plasma Concentration Following ALXN2050 Administration At Steady-state (Tmax,ss)

Time Frame: Up to 72 hours postdose

Secondary Outcomes

Number Of Participants Receiving ALXN2050 With Treatment-emergent Adverse Events(Day 1 (postdose) through follow-up (30 [+/- 2] days after last study drug administration)])
Change From Baseline In Complement Alternative Pathway Activity(Baseline, up to 72 hours postdose)
Change From Baseline In Complement Factor D Concentration At 24, 48, And 72 Hours Postdose(Baseline, 24, 48, and 72 hours postdose)
Change From Baseline In Plasma b Fragment Of Complement Factor B Concentration(Baseline, up to 72 hours postdose)